主营介绍

  • 产品类型:

    医药

  • 产品名称:

    药品 设备及技术

  • 经营范围:

    中、西生化药品生产、销售。软件开发、信息技术咨询服务、自有房地产经营活动、其他专业技术服务业、技术推广服务。(依法须经批准的项目,经相关部门批准后方可开展经营活动。)

运营业务数据

最新公告日期:2018-04-28 
业务名称 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2014-06-30
药品销量(片) 1.96亿 2.81亿 - - -
诊断仪器销量(台) 853.00 676.00 - - -
电力销量(千瓦时) - 47.69亿 - - -
复方鳖甲软肝片销量(片) - - 2.64亿 - -
诊断设备销量(台) - - 558.00 - -
壳脂胶囊销售(粒) - - - 1474.10万 -
软肝片销售(片) - - - 2.45亿 -
壳脂胶囊发货量(粒) - - - - 673.00万
软肝片发货量(片) - - - - 1.07亿
Fibroscan产品销量(台) - - - - 257.00

主营构成分析

{"2018-06-30":{"YYSR":{"2":[["\u8bbe\u5907\u53ca\u6280\u672f","19398.67"],["\u836f\u54c1","17293.65"],["\u5176\u4ed6","1654.01"]],"3":[["\u56fd\u5916","19398.67"],["\u56fd\u5185","18947.66"]]},"YYCB":{"2":[["\u8bbe\u5907\u53ca\u6280\u672f","2856.15"],["\u836f\u54c1","8482.89"],["\u5176\u4ed6","671.38"]],"3":[["\u56fd\u5916","2856.15"],["\u56fd\u5185","9154.28"]]},"LRBL":{"2":[["\u8bbe\u5907\u53ca\u6280\u672f","62.81"],["\u836f\u54c1","33.46"],["\u5176\u4ed6","3.73"]],"3":[["\u56fd\u5916","62.81"],["\u56fd\u5185","37.19"]]}},"2017-12-31":{"YYSR":{"1":[["\u533b\u7597\u5668\u68b0\u4e1a","49353.47"],["\u836f\u54c1\u53ca\u751f\u7269\u5236\u54c1\u4e1a","35614.04"]],"2":[["\u8bbe\u5907\u53ca\u6280\u672f","49353.47"],["\u81ea\u6709\u836f\u54c1","23200.03"],["\u6d41\u901a\u836f\u54c1","7560.80"],["\u5176\u4ed6","4853.20"]],"3":[["\u56fd\u5916","49353.47"],["\u56fd\u5185","35614.04"]]},"YYCB":{"1":[["\u533b\u7597\u5668\u68b0\u4e1a",""],["\u836f\u54c1\u53ca\u751f\u7269\u5236\u54c1\u4e1a",""]],"2":[["\u8bbe\u5907\u53ca\u6280\u672f","6068.11"],["\u81ea\u6709\u836f\u54c1","8146.84"],["\u6d41\u901a\u836f\u54c1","5309.57"],["\u5176\u4ed6","2355.83"]],"3":[["\u56fd\u5916","6068.11"],["\u56fd\u5185","15812.24"]]},"LRBL":{"1":[["\u533b\u7597\u5668\u68b0\u4e1a",""],["\u836f\u54c1\u53ca\u751f\u7269\u5236\u54c1\u4e1a",""]],"2":[["\u8bbe\u5907\u53ca\u6280\u672f","68.61"],["\u81ea\u6709\u836f\u54c1","23.86"],["\u6d41\u901a\u836f\u54c1","3.57"],["\u5176\u4ed6","3.96"]],"3":[["\u56fd\u5916","68.61"],["\u56fd\u5185","31.39"]]}},"2017-06-30":{"YYSR":{"2":[["\u8bbe\u5907\u53ca\u6280\u672f","23587.48"],["\u836f\u54c1","14951.13"],["\u5176\u4ed6","2228.73"]],"3":[["\u6d77\u5916\u5730\u533a","23587.48"],["\u4e2d\u56fd\u5927\u9646","17179.86"]]},"YYCB":{"2":[["\u8bbe\u5907\u53ca\u6280\u672f","2557.02"],["\u836f\u54c1","6100.77"],["\u5176\u4ed6","1049.04"]],"3":[["\u6d77\u5916\u5730\u533a","2557.02"],["\u4e2d\u56fd\u5927\u9646","7149.81"]]},"LRBL":{"2":[["\u8bbe\u5907\u53ca\u6280\u672f","67.71"],["\u836f\u54c1","28.49"],["\u5176\u4ed6","3.80"]],"3":[["\u6d77\u5916\u5730\u533a","67.71"],["\u4e2d\u56fd\u5927\u9646","32.29"]]}}}
{"YYSR":{"chartWrap2":[{"name":"\u8bbe\u5907\u53ca\u6280\u672f","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[19398.67,49353.47,23587.48],"columnData":[50.59,58.09,57.86],"unit":["1.94\u4ebf","4.94\u4ebf","2.36\u4ebf"]},{"name":"\u836f\u54c1","timeData":["2018-06-30","2017-06-30"],"lineData":[17293.65,14951.13],"columnData":[45.1,36.67],"unit":["1.73\u4ebf","1.50\u4ebf"]},{"name":"\u5176\u4ed6","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[1654.01,4853.2,2228.73],"columnData":[4.31,5.71,5.47],"unit":["1654.01\u4e07","4853.20\u4e07","2228.73\u4e07"]},{"name":"\u81ea\u6709\u836f\u54c1","timeData":["2017-12-31"],"lineData":[23200.03],"columnData":[27.3],"unit":["2.32\u4ebf"]},{"name":"\u6d41\u901a\u836f\u54c1","timeData":["2017-12-31"],"lineData":[7560.8],"columnData":[8.9],"unit":["7560.80\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5916","timeData":["2018-06-30","2017-12-31"],"lineData":[19398.67,49353.47],"columnData":[50.59,58.09],"unit":["1.94\u4ebf","4.94\u4ebf"]},{"name":"\u56fd\u5185","timeData":["2018-06-30","2017-12-31"],"lineData":[18947.66,35614.04],"columnData":[49.41,41.91],"unit":["1.89\u4ebf","3.56\u4ebf"]},{"name":"\u6d77\u5916\u5730\u533a","timeData":["2017-06-30"],"lineData":[23587.48],"columnData":[57.86],"unit":["2.36\u4ebf"]},{"name":"\u4e2d\u56fd\u5927\u9646","timeData":["2017-06-30"],"lineData":[17179.86],"columnData":[42.14],"unit":["1.72\u4ebf"]}],"chartWrap1":[{"name":"\u533b\u7597\u5668\u68b0\u4e1a","timeData":["2017-12-31"],"lineData":[49353.47],"columnData":[58.09],"unit":["4.94\u4ebf"]},{"name":"\u836f\u54c1\u53ca\u751f\u7269\u5236\u54c1\u4e1a","timeData":["2017-12-31"],"lineData":[35614.04],"columnData":[41.91],"unit":["3.56\u4ebf"]}]},"YYCB":{"chartWrap2":[{"name":"\u8bbe\u5907\u53ca\u6280\u672f","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[2856.15,6068.11,2557.02],"columnData":[23.78,27.73,26.34],"unit":["2856.15\u4e07","6068.11\u4e07","2557.02\u4e07"]},{"name":"\u836f\u54c1","timeData":["2018-06-30","2017-06-30"],"lineData":[8482.89,6100.77],"columnData":[70.63,62.85],"unit":["8482.89\u4e07","6100.77\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[671.38,2355.83,1049.04],"columnData":[5.59,10.77,10.81],"unit":["671.38\u4e07","2355.83\u4e07","1049.04\u4e07"]},{"name":"\u81ea\u6709\u836f\u54c1","timeData":["2017-12-31"],"lineData":[8146.84],"columnData":[37.23],"unit":["8146.84\u4e07"]},{"name":"\u6d41\u901a\u836f\u54c1","timeData":["2017-12-31"],"lineData":[5309.57],"columnData":[24.27],"unit":["5309.57\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5916","timeData":["2018-06-30","2017-12-31"],"lineData":[2856.15,6068.11],"columnData":[23.78,27.73],"unit":["2856.15\u4e07","6068.11\u4e07"]},{"name":"\u56fd\u5185","timeData":["2018-06-30","2017-12-31"],"lineData":[9154.28,15812.24],"columnData":[76.22,72.27],"unit":["9154.28\u4e07","1.58\u4ebf"]},{"name":"\u6d77\u5916\u5730\u533a","timeData":["2017-06-30"],"lineData":[2557.02],"columnData":[26.34],"unit":["2557.02\u4e07"]},{"name":"\u4e2d\u56fd\u5927\u9646","timeData":["2017-06-30"],"lineData":[7149.81],"columnData":[73.66],"unit":["7149.81\u4e07"]}],"chartWrap1":[{"name":"\u533b\u7597\u5668\u68b0\u4e1a","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u836f\u54c1\u53ca\u751f\u7269\u5236\u54c1\u4e1a","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}]},"LRBL":{"chartWrap2":[{"name":"\u8bbe\u5907\u53ca\u6280\u672f","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[62.81,68.61,67.71],"columnData":[62.81,68.61,67.71],"unit":["62.81\u4e07","68.61\u4e07","67.71\u4e07"]},{"name":"\u836f\u54c1","timeData":["2018-06-30","2017-06-30"],"lineData":[33.46,28.49],"columnData":[33.46,28.49],"unit":["33.46\u4e07","28.49\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2018-06-30","2017-12-31","2017-06-30"],"lineData":[3.73,3.96,3.8],"columnData":[3.73,3.96,3.8],"unit":["3.73\u4e07","3.96\u4e07","3.80\u4e07"]},{"name":"\u81ea\u6709\u836f\u54c1","timeData":["2017-12-31"],"lineData":[23.86],"columnData":[23.86],"unit":["23.86\u4e07"]},{"name":"\u6d41\u901a\u836f\u54c1","timeData":["2017-12-31"],"lineData":[3.57],"columnData":[3.57],"unit":["3.57\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5916","timeData":["2018-06-30","2017-12-31"],"lineData":[62.81,68.61],"columnData":[62.81,68.61],"unit":["62.81\u4e07","68.61\u4e07"]},{"name":"\u56fd\u5185","timeData":["2018-06-30","2017-12-31"],"lineData":[37.19,31.39],"columnData":[37.19,31.39],"unit":["37.19\u4e07","31.39\u4e07"]},{"name":"\u6d77\u5916\u5730\u533a","timeData":["2017-06-30"],"lineData":[67.71],"columnData":[67.71],"unit":["67.71\u4e07"]},{"name":"\u4e2d\u56fd\u5927\u9646","timeData":["2017-06-30"],"lineData":[32.29],"columnData":[32.29],"unit":["32.29\u4e07"]}],"chartWrap1":[{"name":"\u533b\u7597\u5668\u68b0\u4e1a","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u836f\u54c1\u53ca\u751f\u7269\u5236\u54c1\u4e1a","timeData":["2017-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 设备及技术 1.94亿 50.59% 2856.15万 23.78% 62.81% 85.28%
药品 1.73亿 45.10% 8482.89万 70.63% 33.46% 50.95%
其他 1654.01万 4.31% 671.38万 5.59% 3.73% 59.41%
按地区 国外 1.94亿 50.59% 2856.15万 23.78% 62.81% 85.28%
国内 1.89亿 49.41% 9154.28万 76.22% 37.19% 51.69%

董事会经营评述

  一、概述
  公司紧跟医疗改革步伐,围绕既定的发展战略,通过整合全线的肝病治疗药品、创新的科技诊断设备以及先进的慢病管理体系等优势资源进一步开展与医院的深度合作,打造慢病管理医疗服务平台,持续研发并推广满足不同市场需求诊断肝病产品,丰富药品销售模式,控制企业生产成本,为肝病以及其它慢性疾病患者提供全面的解决方案。
  报告期内,公司实现营业总收入387,877,244.39元,比上年同期下降5.82%,其中药品实现收入172,936,463.44元,比上年同期增长15.67%。由于销售模式的调整,法国子公司销售收入同比下降,导致合并收入与上年同期略有下降。
  报告期内,公司实现营业利润8... 查看全部▼

  一、概述
  公司紧跟医疗改革步伐,围绕既定的发展战略,通过整合全线的肝病治疗药品、创新的科技诊断设备以及先进的慢病管理体系等优势资源进一步开展与医院的深度合作,打造慢病管理医疗服务平台,持续研发并推广满足不同市场需求诊断肝病产品,丰富药品销售模式,控制企业生产成本,为肝病以及其它慢性疾病患者提供全面的解决方案。
  报告期内,公司实现营业总收入387,877,244.39元,比上年同期下降5.82%,其中药品实现收入172,936,463.44元,比上年同期增长15.67%。由于销售模式的调整,法国子公司销售收入同比下降,导致合并收入与上年同期略有下降。
  报告期内,公司实现营业利润87,290,842.49元,比上年同期增长27.83%,实现利润总额83,494,011.14元,比上年同期增长27.81%,实现净利润66,717,215.19元,比上年同期增长28.88%,实现归属于上市公司股东的净利润48,221,200.83元,比上年同期增长21.71%,主要增长原因为:一是公司主导药品复方鳖甲软肝片的销量在报告期内同比回升;二是本报告期费用同比下降;三是法国Echosens公司的利润率有所提升。
  报告期内,公司发生营业总成本304,307,826.58元,较上年同期减少12.28%,其中销售费用比上年同期下降7.48%,管理费用比上年同期下降37.06%,财务费用比上年同期下降116.03%,主要原因上年同期确认了法国子公司IPO相关费用以及本期美元对欧元汇率上升。
  报告期内,公司研发持续投入,本期研发投入40,200,930.01元,占营业总收入的10.36%。
  报告期末,公司资产总额为2,170,641,854.70元,同比下降13.27%,归属于上市公司普通股股东权益为1,405,421,286.21元,同比下降6.46%。总资产和归属于上市公司股东的净资产下降的主要原因为2018年上半年法国子公司分红所致。

  二、公司面临的风险和应对措施
  1、主营业务单一的风险
  公司目前的收入结构中,主营业务仍主要集中在肝纤维化诊疗药品和肝脏诊断设备,其他业务在报告期内贡献相对较低。
  应对措施:公司将通过持续的并购努力拓展业务范围,在医疗器械、治疗药品和医疗服务三方面努力拓展,逐步实现各资源板块目标,使各业务模块均衡发展,提升公司盈利能力和抗风险能力。
  2、行业竞争及行业政策的风险
  随着全民健康意识的提高和医疗保障体制的进一步健全,肝病诊断、治疗未来的市场潜力巨大,会有更多的企业进入肝病诊疗市场,现有的企业也会加大市场投入和产品的研发。
  行业的整体竞争将更加剧烈,对公司产品销售和新产品研发都将产生压力。随着医药卫生体制改革的推进,医药分开、医生多点执业、分级诊疗等政策的进一步出台和落实,将带来医疗行业的新的机遇与竞争,将对公司持续提升市场竞争力与适应行业政策提出新的挑战。
  应对措施:面对行业竞争日益加剧,公司将加快战略转型的步伐,积极推进业务结构调整,加速非肝病领域的器械、药品和医疗服务的业务布局,增加持续盈利的业务种类。
  3、主要原材料价格波动带来产品毛利率波动的风险
  公司主要业务药品的原材料包括天然冬虫夏草、鳖甲、三七等,其中,冬虫夏草是公司主导药品复方鳖甲软肝片的最主要原材料。冬虫夏草的采购价格与上年同期相比略有上升,软肝片毛利率相比去年有所下降。未来冬虫夏草的价格仍存在波动风险,从而导致产品毛利率波动的风险。
  应对措施:为减小冬虫夏草价格波动的影响,公司主要采取三方面措施,第一,公司指派专人深入一线产地,利用虫草产新的有利时机直接收购,争取降低直接采购成本。第二,公司采取预付收购款的方式,提前锁定收购价格。第三,进一步加强采购价格制度和流程管理。此外,公司还将大力拓展业务范围,丰富公司产品品种和业务结构,从根本上缓解冬虫夏草价格波动对公司经营业绩的影响。
  4、肝病诊断产品和技术的开发风险
  公司目前的研发重点在肝纤维化诊断领域,公司将持续开发基于物理、血液、生化和基因检测的系列诊断产品,此外,还将持续整合各种肝病检测手段,应用医学信息技术工具,开发肝病诊断评估系统,为医生和患者提供一体化的肝病诊断和患者管理工具。因此,未来的研发过程中容易受到不可预测因素的影响,存在一定的技术开发风险。
  应对措施:针对技术开发风险,公司将研发工作的重心向法国倾斜,子公司法国Echosens拥有一支技术领先的肝病诊断技术研发团队,会紧密的结合肝病诊断方法的发展趋势,保持肝病评估领域的领先优势。此外,法国Echosens还将通过国际并购与合作,获得更多更有效的诊断技术产品,这些肝病诊断技术都将成为公司诊断系列产品的重要组成部分。

  三、核心竞争力分析
  医疗器械业报告期内,公司核心竞争力没有发生重要变化,没有发生因核心管理团队或关键技术人员离职、设备或技术升级换代、特许经营权丧失等导致公司核心竞争力受到影响。 收起▲